-
November 25, 2021 The Psychedelic Sector has Reached “Escape Velocity” | An interview with Cybin’s CEO (CYBN)In this episode, James, The Psychedelic Investor, sits down with Doug Drysdale, CEO of Cybin...
-
November 24, 2021 PharmaTher Believes Ketamine Could Treat This Rare Neurological ConditionThe company is also exploring if ketamine can treat other neurological conditions, including Parkinson’s Disease,...
-
November 24, 2021 How the COVID Pandemic Inspired Wakeful Travel’s Psychedelic Integration JournalsA travel journal company pivots from external trips to those unfolding in the mind, and...
-
November 23, 2021 Does Jon Stewart Microdose Magic Mushrooms? | Plus Pirate EyeDoes Jon Stewart Microdosing Magic Mushrooms? Have you ever wanted to try microdosing magic mushrooms...
-
November 21, 2021 A Deep Dive Into MindMed’s Microdosing Program: Project Flow | Plus a NEW LSD Microdosing StudyIn today’s episode, we look at MindMed’s (Nasdaq: MNMD, NEO: MMED) Project Flow, which is...
-
November 19, 2021 Psychedelic Business Spotlight: November 19This week in psychedelic business news: Companies partner on new dosage method; MindMed investigates LSD...
-
November 18, 2021 We NEED to Talk about the Compass Pathways Psilocybin-for-Depression Trial Results: A WIN for CMPS??In today's episode, we discuss the results of the much awaited phase 2b clinical trial...
-
November 17, 2021 Atai Life Sciences, Compass Pathways, MindMed & Cybin’s Q3 Financial Results Analysis – What’s Next?Analyzing the Quarter 3 financial results of atai Life Sciences (Nasdaq: ATAI), Compass Pathways (Nasdaq:...
-
November 12, 2021 Psychedelic Business Spotlight: November 12This week in psychedelic business news: two of the biggest players in the industry unveil...
-
November 9, 2021 Largest Psilocybin Therapy Trial Ever Conducted Shows Depressive Symptoms Rapidly Reduce“A single dose of psilocybin generated a rapid response that lasted up to 12 weeks,”...
